Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US

Gains 180 Days Of CGT Exclusivity For Generic Of Ortho Evra Contraceptive Patch

Executive Summary

Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.

You may also be interested in...



Viatris Focuses On Being First In Race For Eylea Biosimilar

Viatris has reiterated the strength of its biosimilars and complex generics pipeline, highlighting opportunities including biosimilar Eylea, Botox and once-a-month Copaxone.

Amneal Aims To Bolster Generics Margins

Amneal says it is taking initiatives to improve its generics margins by improving its manufacturing and supply chain, after its generics segment was sales drop by 11% in the first quarter. Amneal is aiming to deliver six to seven high-value products annually, while the company is also looking to launch three biosimilars in the next couple of years.

Amneal’s Generics Business Reinvigorated By New Launches

As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel